0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Allergic Rhinitis Market Insight Epidemiology and Market Forecast 2028
Published Date: February 2019
|
Report Code: DELV-Mark-09
Home | Category |Health |Health Conditions |Allergies
Allergic Rhinitis Market Insight Epidemiology and Market Forecast  2028

Allergic Rhinitis Market Insight Epidemiology and Market Forecast 2028

Code: DELV-Mark-09
Report
February 2019
100 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Allergic Rhinitis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Allergic Rhinitis epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Allergic Rhinitis Understanding and Treatment Algorithm
The market report provides the overview of the Allergic Rhinitis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Allergic Rhinitis Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Allergic Rhinitis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Allergic Rhinitis Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Allergic Rhinitis Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Allergic Rhinitis market.

Allergic Rhinitis Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Allergic Rhinitis Report Insights
• Patient Population in Allergic Rhinitis
• Therapeutic Approaches in Allergic Rhinitis
• Allergic Rhinitis Pipeline Analysis
• Allergic Rhinitis Market Size and Trends
• Allergic Rhinitis Market Opportunities
• Impact of upcoming Therapies in Allergic Rhinitis

Allergic Rhinitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Allergic Rhinitis Report Assessment
• Current Treatment Practices in Allergic Rhinitis
• Unmet Needs in Allergic Rhinitis
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Allergic Rhinitis market
• Organize sales and marketing efforts by identifying the best opportunities for Allergic Rhinitis market
• To understand the future market competition in the Allergic Rhinitis market.

  1. Report Introduction
    2. Allergic Rhinitis Market Overview at a Glance
    2.1. Market Share Distribution of Allergic Rhinitis in 2016
    2.2. Market Share Distribution of Allergic Rhinitis in 2028
    3. Disease Background and Overview: Allergic Rhinitis
    3.1. Introduction
    3.2. Symptoms
    3.3. Etiology
    3.4. Risk Factors
    3.5. Pathophysiology
    3.6. Diagnosis
    3.7. Treatment
    4. Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Allergic Rhinitis in 7MM
    4.3. Total Prevalent Patient Population of Allergic Rhinitis in 7MM – By Countries
    5. Epidemiology of Allergic Rhinitis by Countries
    5.1. United States
    5.1.1. Assumptions and Rationale
    5.1.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.1.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.1.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.1.5. Diagnosed Cases of the Allergic Rhinitis
    5.1.6. Treatable Cases of the Allergic Rhinitis
    5.2. EU5
    5.3. Assumptions and Rationale
    5.4. Germany
    5.4.1. Assumptions and Rationale
    5.4.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.4.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.4.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.4.5. Diagnosed Cases of the Allergic Rhinitis
    5.4.6. Treatable Cases of the Allergic Rhinitis
    5.5. France
    5.5.1. Assumptions and Rationale
    5.5.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.5.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.5.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.5.5. Diagnosed Cases of the Allergic Rhinitis
    5.5.6. Treatable Cases of the Allergic Rhinitis
    5.6. Italy
    5.6.1. Assumptions and Rationale
    5.6.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.6.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.6.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.6.5. Diagnosed Cases of the Allergic Rhinitis
    5.6.6. Treatable Cases of the Allergic Rhinitis
    5.7. Spain
    5.7.1. Assumptions and Rationale
    5.7.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.7.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.7.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.7.5. Diagnosed Cases of the Allergic Rhinitis
    5.7.6. Treatable Cases of the Allergic Rhinitis
    5.8. United Kingdom
    5.8.1. Assumptions and Rationale
    5.8.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.8.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.8.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.8.5. Diagnosed Cases of the Allergic Rhinitis
    5.8.6. Treatable Cases of the Allergic Rhinitis
    5.9. Japan
    5.9.1. Assumptions and Rationale
    5.9.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.9.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.9.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.9.5. Diagnosed Cases of the Allergic Rhinitis
    5.9.6. Treatable Cases of the Allergic Rhinitis
    6. Current Treatment & Medical practices
    6.1. Treatment Algorithm
    6.2. Treatment Guidelines
    7. Unmet Needs of the Allergic Rhinitis
    8. Marketed Therapies
    8.1. Drug A: Company 1
    8.1.1. Drug Description
    8.1.2. Mechanism of Action
    8.1.3. Regulatory Milestones
    8.1.4. Advantages & Disadvantages
    8.1.5. Product Profile
    8.2. Drug B: Company 2
    8.2.1. Drug Description
    8.2.2. Mechanism of Action
    8.2.3. Regulatory Milestones
    8.2.4. Advantages & Disadvantages
    8.2.5. Product Profile
    9. Pipeline Therapies – At a glance
    10. Key Cross Competition
    11. Emerging Therapies for Allergic Rhinitis
    11.1. Drug C: Company 3
    11.1.1. Drug Description
    11.1.2. Clinical Trials Details
    11.1.3. Safety and Efficacy Profile
    11.1.4. Advantages & Disadvantages
    11.1.5. Pipeline Development Activities
    11.1.6. Product Profile
    11.2. Drug D: Company 4
    11.2.1. Drug Description
    11.2.2. Clinical Trials Details
    11.2.3. Safety and Efficacy Profile
    11.2.4. Advantages & Disadvantages
    11.2.5. Pipeline Development Activities
    11.2.6. Product Profile
    12. Allergic Rhinitis : 7MM Market Analysis
    12.1. 7MM Market Size of Allergic Rhinitis
    12.2. 7MM Percentage Share of drugs marketed for Allergic Rhinitis
    12.3. 7MM Market Sales of Allergic Rhinitis by Products
    13. Allergic Rhinitis : Country-Wise Market Analysis
    13.1. United States
    13.1.1. Market Size of Allergic Rhinitis in United States
    13.1.2. Percentage Share of drugs marketed for Allergic Rhinitis in United States
    13.1.3. Market Sales of Allergic Rhinitis by Products in United States
    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2. EU-5
    13.2.1. Germany
    13.2.1.1. Market Size of Allergic Rhinitis in Germany
    13.2.1.2. Percentage Share of drugs marketed for Allergic Rhinitis in Germany
    13.2.1.3. Market Sales of Allergic Rhinitis by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.2. France
    13.2.2.1. Market Size of Allergic Rhinitis in France
    13.2.2.2. Percentage Share of drugs marketed for Allergic Rhinitis in France
    13.2.2.3. Market Sales of Allergic Rhinitis by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.3. Italy
    13.2.3.1. Market Size of Allergic Rhinitis in Italy
    13.2.3.2. Percentage Share of drugs marketed for Allergic Rhinitis in Italy
    13.2.3.3. Market Sales of Allergic Rhinitis by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.4. Spain
    13.2.4.1. Market Size of Allergic Rhinitis in Spain
    13.2.4.2. Percentage Share of drugs marketed for Allergic Rhinitis in Spain
    13.2.4.3. Market Sales of Allergic Rhinitis by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.5. United Kingdom
    13.2.5.1. Market Size of Allergic Rhinitis in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Allergic Rhinitis in United Kingdom
    13.2.5.3. Market Sales of Allergic Rhinitis by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.3. Japan
    13.3.1. Market Size of Allergic Rhinitis in Japan
    13.3.2. Percentage Share of drugs marketed for Allergic Rhinitis in Japan
    13.3.3. Market Sales of Allergic Rhinitis by Products in Japan
    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    14. Market Drivers
    15. Market Barriers
    16. Appendix
    17. Report Methodology
    17.1. Sources
    18. DelveInsight Capabilities
    19. Disclaimer
    20. About DelveInsight

    *Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM
Table 2: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Allergic Rhinitis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Allergic Rhinitis in United States (2016-2028)
Table 5: Sex- Specific Cases of the Allergic Rhinitis in United States (2016-2028)
Table 6: Diagnosed Cases of the Allergic Rhinitis in United States (2016-2028)
Table 7: Treatable Cases of the Allergic Rhinitis in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Allergic Rhinitis in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 11: Diagnosed Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 12: Treatable Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Allergic Rhinitis in France (2016-2028)
Table 14: Sub-Type Specific cases of the Allergic Rhinitis in France (2016-2028)
Table 15: Sex- Specific Cases of the Allergic Rhinitis in France (2016-2028)
Table 16: Diagnosed Cases of the Allergic Rhinitis in France (2016-2028)
Table 17: Treatable Cases of the Allergic Rhinitis in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Allergic Rhinitis in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 21: Diagnosed Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 22: Treatable Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Allergic Rhinitis in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 26: Diagnosed Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 27: Treatable Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Allergic Rhinitis in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Allergic Rhinitis in UK (2016-2028)
Table 30: Sex- Specific Cases of the Allergic Rhinitis in UK (2016-2028)
Table 31: Diagnosed Cases of the Allergic Rhinitis in UK (2016-2028)
Table 32: Treatable Cases of the Allergic Rhinitis in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Allergic Rhinitis in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 36: Diagnosed Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 37: Treatable Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 42:7MM- Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 45: United States-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 48: Germany-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 51: France-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 54: Italy-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 57: Spain-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 60:UK-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 63: Japan-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Allergic Rhinitis in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 6: Diagnosed Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 7: Treatable Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 12: Treatable Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Allergic Rhinitis in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Allergic Rhinitis in France (2016-2028)
Figure 15: Sex- Specific Cases of the Allergic Rhinitis in France (2016-2028)
Figure 16: Diagnosed Cases of the Allergic Rhinitis in France (2016-2028)
Figure 17: Treatable Cases of the Allergic Rhinitis in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 22: Treatable Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 27: Treatable Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Allergic Rhinitis in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 31: Diagnosed Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 32: Treatable Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 37: Treatable Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 42:7MM- Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 45: United States-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 48: Germany-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 51: France-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 54: Italy-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 57: Spain-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 60:UK-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 63: Japan-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)

DelveInsight's "Allergic Rhinitis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Allergic Rhinitis epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Allergic Rhinitis Understanding and Treatment Algorithm
The market report provides the overview of the Allergic Rhinitis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Allergic Rhinitis Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Allergic Rhinitis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Allergic Rhinitis Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Allergic Rhinitis Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Allergic Rhinitis market.

Allergic Rhinitis Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Allergic Rhinitis Report Insights
• Patient Population in Allergic Rhinitis
• Therapeutic Approaches in Allergic Rhinitis
• Allergic Rhinitis Pipeline Analysis
• Allergic Rhinitis Market Size and Trends
• Allergic Rhinitis Market Opportunities
• Impact of upcoming Therapies in Allergic Rhinitis

Allergic Rhinitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Allergic Rhinitis Report Assessment
• Current Treatment Practices in Allergic Rhinitis
• Unmet Needs in Allergic Rhinitis
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Allergic Rhinitis market
• Organize sales and marketing efforts by identifying the best opportunities for Allergic Rhinitis market
• To understand the future market competition in the Allergic Rhinitis market.

Read More
  1. Report Introduction
    2. Allergic Rhinitis Market Overview at a Glance
    2.1. Market Share Distribution of Allergic Rhinitis in 2016
    2.2. Market Share Distribution of Allergic Rhinitis in 2028
    3. Disease Background and Overview: Allergic Rhinitis
    3.1. Introduction
    3.2. Symptoms
    3.3. Etiology
    3.4. Risk Factors
    3.5. Pathophysiology
    3.6. Diagnosis
    3.7. Treatment
    4. Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Allergic Rhinitis in 7MM
    4.3. Total Prevalent Patient Population of Allergic Rhinitis in 7MM – By Countries
    5. Epidemiology of Allergic Rhinitis by Countries
    5.1. United States
    5.1.1. Assumptions and Rationale
    5.1.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.1.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.1.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.1.5. Diagnosed Cases of the Allergic Rhinitis
    5.1.6. Treatable Cases of the Allergic Rhinitis
    5.2. EU5
    5.3. Assumptions and Rationale
    5.4. Germany
    5.4.1. Assumptions and Rationale
    5.4.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.4.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.4.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.4.5. Diagnosed Cases of the Allergic Rhinitis
    5.4.6. Treatable Cases of the Allergic Rhinitis
    5.5. France
    5.5.1. Assumptions and Rationale
    5.5.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.5.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.5.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.5.5. Diagnosed Cases of the Allergic Rhinitis
    5.5.6. Treatable Cases of the Allergic Rhinitis
    5.6. Italy
    5.6.1. Assumptions and Rationale
    5.6.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.6.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.6.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.6.5. Diagnosed Cases of the Allergic Rhinitis
    5.6.6. Treatable Cases of the Allergic Rhinitis
    5.7. Spain
    5.7.1. Assumptions and Rationale
    5.7.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.7.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.7.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.7.5. Diagnosed Cases of the Allergic Rhinitis
    5.7.6. Treatable Cases of the Allergic Rhinitis
    5.8. United Kingdom
    5.8.1. Assumptions and Rationale
    5.8.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.8.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.8.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.8.5. Diagnosed Cases of the Allergic Rhinitis
    5.8.6. Treatable Cases of the Allergic Rhinitis
    5.9. Japan
    5.9.1. Assumptions and Rationale
    5.9.2. Prevalent/Incident Cases of the Allergic Rhinitis
    5.9.3. Sub-Type Specific cases of the Allergic Rhinitis *
    5.9.4. Sex- Specific Cases of the Allergic Rhinitis *
    5.9.5. Diagnosed Cases of the Allergic Rhinitis
    5.9.6. Treatable Cases of the Allergic Rhinitis
    6. Current Treatment & Medical practices
    6.1. Treatment Algorithm
    6.2. Treatment Guidelines
    7. Unmet Needs of the Allergic Rhinitis
    8. Marketed Therapies
    8.1. Drug A: Company 1
    8.1.1. Drug Description
    8.1.2. Mechanism of Action
    8.1.3. Regulatory Milestones
    8.1.4. Advantages & Disadvantages
    8.1.5. Product Profile
    8.2. Drug B: Company 2
    8.2.1. Drug Description
    8.2.2. Mechanism of Action
    8.2.3. Regulatory Milestones
    8.2.4. Advantages & Disadvantages
    8.2.5. Product Profile
    9. Pipeline Therapies – At a glance
    10. Key Cross Competition
    11. Emerging Therapies for Allergic Rhinitis
    11.1. Drug C: Company 3
    11.1.1. Drug Description
    11.1.2. Clinical Trials Details
    11.1.3. Safety and Efficacy Profile
    11.1.4. Advantages & Disadvantages
    11.1.5. Pipeline Development Activities
    11.1.6. Product Profile
    11.2. Drug D: Company 4
    11.2.1. Drug Description
    11.2.2. Clinical Trials Details
    11.2.3. Safety and Efficacy Profile
    11.2.4. Advantages & Disadvantages
    11.2.5. Pipeline Development Activities
    11.2.6. Product Profile
    12. Allergic Rhinitis : 7MM Market Analysis
    12.1. 7MM Market Size of Allergic Rhinitis
    12.2. 7MM Percentage Share of drugs marketed for Allergic Rhinitis
    12.3. 7MM Market Sales of Allergic Rhinitis by Products
    13. Allergic Rhinitis : Country-Wise Market Analysis
    13.1. United States
    13.1.1. Market Size of Allergic Rhinitis in United States
    13.1.2. Percentage Share of drugs marketed for Allergic Rhinitis in United States
    13.1.3. Market Sales of Allergic Rhinitis by Products in United States
    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2. EU-5
    13.2.1. Germany
    13.2.1.1. Market Size of Allergic Rhinitis in Germany
    13.2.1.2. Percentage Share of drugs marketed for Allergic Rhinitis in Germany
    13.2.1.3. Market Sales of Allergic Rhinitis by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.2. France
    13.2.2.1. Market Size of Allergic Rhinitis in France
    13.2.2.2. Percentage Share of drugs marketed for Allergic Rhinitis in France
    13.2.2.3. Market Sales of Allergic Rhinitis by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.3. Italy
    13.2.3.1. Market Size of Allergic Rhinitis in Italy
    13.2.3.2. Percentage Share of drugs marketed for Allergic Rhinitis in Italy
    13.2.3.3. Market Sales of Allergic Rhinitis by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.4. Spain
    13.2.4.1. Market Size of Allergic Rhinitis in Spain
    13.2.4.2. Percentage Share of drugs marketed for Allergic Rhinitis in Spain
    13.2.4.3. Market Sales of Allergic Rhinitis by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.5. United Kingdom
    13.2.5.1. Market Size of Allergic Rhinitis in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Allergic Rhinitis in United Kingdom
    13.2.5.3. Market Sales of Allergic Rhinitis by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.3. Japan
    13.3.1. Market Size of Allergic Rhinitis in Japan
    13.3.2. Percentage Share of drugs marketed for Allergic Rhinitis in Japan
    13.3.3. Market Sales of Allergic Rhinitis by Products in Japan
    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    14. Market Drivers
    15. Market Barriers
    16. Appendix
    17. Report Methodology
    17.1. Sources
    18. DelveInsight Capabilities
    19. Disclaimer
    20. About DelveInsight

    *Indication Specific
Read More

List of Tables

Table 1: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM
Table 2: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Allergic Rhinitis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Allergic Rhinitis in United States (2016-2028)
Table 5: Sex- Specific Cases of the Allergic Rhinitis in United States (2016-2028)
Table 6: Diagnosed Cases of the Allergic Rhinitis in United States (2016-2028)
Table 7: Treatable Cases of the Allergic Rhinitis in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Allergic Rhinitis in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 11: Diagnosed Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 12: Treatable Cases of the Allergic Rhinitis in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Allergic Rhinitis in France (2016-2028)
Table 14: Sub-Type Specific cases of the Allergic Rhinitis in France (2016-2028)
Table 15: Sex- Specific Cases of the Allergic Rhinitis in France (2016-2028)
Table 16: Diagnosed Cases of the Allergic Rhinitis in France (2016-2028)
Table 17: Treatable Cases of the Allergic Rhinitis in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Allergic Rhinitis in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 21: Diagnosed Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 22: Treatable Cases of the Allergic Rhinitis in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Allergic Rhinitis in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 26: Diagnosed Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 27: Treatable Cases of the Allergic Rhinitis in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Allergic Rhinitis in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Allergic Rhinitis in UK (2016-2028)
Table 30: Sex- Specific Cases of the Allergic Rhinitis in UK (2016-2028)
Table 31: Diagnosed Cases of the Allergic Rhinitis in UK (2016-2028)
Table 32: Treatable Cases of the Allergic Rhinitis in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Allergic Rhinitis in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 36: Diagnosed Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 37: Treatable Cases of the Allergic Rhinitis in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 42:7MM- Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 45: United States-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 48: Germany-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 51: France-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 54: Italy-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 57: Spain-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 60:UK-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Table 63: Japan-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Allergic Rhinitis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Allergic Rhinitis in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 6: Diagnosed Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 7: Treatable Cases of the Allergic Rhinitis in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 12: Treatable Cases of the Allergic Rhinitis in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Allergic Rhinitis in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Allergic Rhinitis in France (2016-2028)
Figure 15: Sex- Specific Cases of the Allergic Rhinitis in France (2016-2028)
Figure 16: Diagnosed Cases of the Allergic Rhinitis in France (2016-2028)
Figure 17: Treatable Cases of the Allergic Rhinitis in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 22: Treatable Cases of the Allergic Rhinitis in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 27: Treatable Cases of the Allergic Rhinitis in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Allergic Rhinitis in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 31: Diagnosed Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 32: Treatable Cases of the Allergic Rhinitis in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 37: Treatable Cases of the Allergic Rhinitis in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 42:7MM- Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 45: United States-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 48: Germany-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 51: France-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 54: Italy-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 57: Spain-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 60:UK-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Allergic Rhinitis in USD MM (2016-2028)
Figure 63: Japan-Market Share Allergic Rhinitis by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Allergic Rhinitis by Therapies in USD MM (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String
0 Items
X
No items in the cart.
$0.0